Abstract Body

Background: Extensively pretreated subjects with virologic failure (VF) may receive salvage regimens containing NRTIs with only residual activity. Once virologic suppression is achieved, their contribution remains elusive. Withdrawing NRTIs with intermediate to complete genotypic resistance (Spanish RIS Resistance Score) when viral load (VL) <50 c/mL could have non-inferior efficacy to their maintenance, with lower potential toxicity and cost.

Methods: Multicenter, randomized, prospective, open study. Subjects with ≥1 prior VF, VL<50 c/mL for ≥ 6 months, any CD4 count, without hep B, receiving ≥2 active drugs (one of them an active boosted PI), and ≥1 NRTI without complete activity, were randomly allocated to stop NRTIs without complete activity (one or both, Exp arm) or to maintain the treatment (Ctrol). No drug changes allowed during last 6 months or at screening. Main endpoint VL<50 c/mL at 48 weeks (Snapshot analysis), non-inferiority margin at -12. EudraCT: 2012-000198-21.

Results: 92 subjects were screened and 90 randomized (Exp, n=45, Ctrol, n=45). Median age 50y old, 80% male, 37% stage C3, 40% chronic hep C, CD4 488 (IQR 355-712) cells, 17 median years on ART. Had received a median of 9 lines of ART, 4 PIs, and a median of 3 (1-4) prior VF. The baseline regimen contained 4 drugs in 46 (51%) subjects, and 3 in 37 (41%). 74 subjects (82%) harbored M184V/I, and the median of TAMs was 3 (2-4; D67X and T215X the most frequent). 32 (71%) subjects removed 1 NRTI (12 TDF, 9 FTC, 8 3TC, 2 ABC, 1 ddI) and 13 (29%) 2 NRTIs (9 TDF/FTC, 3 ABC/3TC, 1 ABC + TDF). In the primary endpoint, 41/45 (91.1%, Exp) and 44/45 (97.8%, Ctrol) had VL<50 c/mL at 48 weeks (dif 6.7%; 95%CI: -17.4, 4.1). In an analysis allowing NRTI reintroduction, rates of VL <50 c/mL at 48 weeks were 95.6% (Exp) and 97.8% (Ctrol) (dif -2.2% 95%CI: -7.2, 2.7). CD4 cell counts remained stable in both arms. One subject developed VF (confirmed VL>200 c/mL, Exp). New resistance mutations were not selected in genotypic resistance tests. There were 10 grade 3/4 adverse events, 5 in each arm (none related to study drugs). There was one death (lung neoplasia, Exp Arm ).

Conclusions: In multitreated patients receiving a successful salvage regimen with at least 2 active drugs (one a boosted PI), the withdrawal of NRTIs without complete activity was safe and associated with high rates of continued virologic suppression at 48 weeks.